We observed that patients with germline BRCA1 pathogenic variants had worse DFS than those with BRCA2 pathogenic variants, mainly due to higher rates of second primary malignancies (predominantly breast and ovarian cancers) irrespective of hormone receptor status, with no difference in DRFI and OS. This evidence concerns the gene NR4A1 and ovarian carcinoma.